ReviewWorld journal of gastroenterology2020
Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?
Review in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- The Effect of Anodal tDCS Over F3 on Reducing Pain and Psychological Distress in Patients With Chronic Gastric Pain.The European journal of neuroscience · 2026Trial
- Microbial signature of pediatric Crohn's disease: Differentiation from functional gastrointestinal disorders and relationship with increased disease activity.Physiological reports · 2026Article
- Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers.The American journal of gastroenterology · 2025Article
- Towards molecular diagnostics of parental alienation.Cellular and molecular life sciences : CMLS · 2025Review
- Dietary and physical activity habits of adults with inflammatory bowel disease in Aotearoa, New Zealand: A cross-sectional study.Nutrition & dietetics : the journal of the Dietitians Association of Australia · 2025Article
- Physiological Data Collected From Wearable Devices Identify and Predict Inflammatory Bowel Disease Flares.Gastroenterology · 2025Observational
- Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons.World journal of clinical pediatrics · 2024Article
- Ultra-processed foods and food additives in gut health and disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Irritable bowel syndrome (IBS): could we decide what is behind?Biologia futura · 2024Review
- Review
- Physical Activity for Quiescent and Mildly Active Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Journal of the Canadian Association of Gastroenterology · 2023Article
- Development of functional gastrointestinal disorder symptoms following laparoscopic cholecystectomy: a prospective cohort study.Frontiers in medicine · 2023Article
- Burden of persistent symptoms in treated coeliac disease: cause, aftermath or merely association?BMJ open gastroenterology · 2022Article
- Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response.International journal of molecular sciences · 2022Review
- [Functional Gastrointestinal Disorders in Patients with Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Review
- Concurrent functional gastrointestinal disorders in patients with inflammatory bowel disease.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
- Behaviour Change Considerations to Promote Physical Activity Participation among Individuals with Quiescent Inflammatory Bowel Disease: Barriers and Facilitators.Advances in rehabilitation science and practiceArticle
- Restraint stress-associated gastrointestinal injury and implications from the Evans blue-fed restraint stress mouse model.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in biological therapies have revolutionalised and redefined treatment targets in inflammatory bowel disease (IBD). There is now a stronger emphasis on achieving the more stringent therapeutic goals of mucosal and histological healing, rather than clinical remission alone. Consequently, the treatment of refractory "functional" gastrointestinal symptoms, often attributed as the aftermath of previous inflammation, has recently become more prominent in quiescent disease. With further expected advances in anti-inflammatory treatments on the horizon, the burden of such symptoms in quiescent disease, which have been relatively neglected, is set to become an even bigger problem. In this article, we highlight the current state of research and understanding in this field, including recent developments and clinical practice guidelines on the diagnosis and management of functional gastrointestinal symptoms, such as irritable bowel syndrome and functional anorectal and pelvic floor disorders, in patients with quiescent IBD. These disorders are not only highly prevalent in these patients, they are often misdiagnosed, and are difficult to treat, with very few evidence-based therapies. Moreover, they are associated with substantial impairment in quality-of-life, considerable morbidity, and psychological distress. There is therefore an urgent need for a change in emphasis towards earlier recognition, positive diagnosis, and targeted treatment for patients with ongoing functional gastrointestinal symptoms in the absence of active IBD. This article also highlights the need for further research to develop much needed evidence-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.